Olink® to Science
The Olink to Science blog aims to inform, inspire, and support you in all things proteomics. Subscribe to stay updated on the latest proteomics research, ideas, and technological developments.
Below is a list of top Olink publications of 2022, a short description of the problem or challenge the researchers set out to solve, and links are at the bottom to access the respective journal article. This brief list covers a wide range of applications of Olink technology, from stratification of patient samples for more efficient clinical trials (Bowman et al.) to determining the mechanism-of-action for a popular diabetes medication which also reduces risk of heart failure (Zanaad et al.) to combining genomics with proteomics to obtain pQTLs to identify new drug targets (Henry et al.)
A broad screen of CSF samples using 11 Olink Target 96 panels analyzed patients with Alzheimer’s Disease with dementia, patients with mild cognitive impairment and who are positive for β-amyloid (MCI Aβ+), and patients with dementia but are negative for β-amyloid (Aβ-). Over a hundred differentially expressed proteins were shown to be dysregulated, and from this data an 8-marker and a 9-marker Olink Focus Panel were designed to discriminate between these three groups with high accuracy (AUC of 0.8-0.99) in an external independent cohort. These marker panels have real diagnostic potential as well as utility in design of clinical trials of drugs targeting various pathological mechanisms of Alzheimer’s Disease.
A five-year old child infected by SARS-CoV-2 developed severe symptoms of arthralgia (joint pain) and thromobocytopenia (abnormally low platelet count), revealing significant dysregulation of their immune system. This condition, called Haploinsufficiency of Suppressor of Cytokine Signaling (SOCS1) is accompanied by excessive B-cell activity, an increase of a type of white blood cell called eosinophils, and high levels of IgE antibodies. The Olink® Target 48 Cytokine panel was used to confirm up-regulation of multiple interferon (IFN)-inducible genes, comparable to dysregulation observed in systemic lupus erythematosus (SLE).
Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder affecting nearly 50 million worldwide; with only 1-in-4 people diagnosed there is a genuine need for discovery of blood-based biomarkers. A recent paper from a group at Harvard and Massachusetts General Hospital looks at a technical evaluation of reproducibility and biological variation in AD patient samples collected over time.
The biological process of a cytokine release storm is a generalized inflammatory response to a pathogen (most recently associated with COVID-19 mortality), or a reaction to a cell-therapy treatment or autoimmune disease (such as primary hemophagocytic lymphohistiocytosis, a severe systemic inflammatory syndrome). Described here are the interaction between the triggered driver cells (both adaptive T-cells and antigen-presenting cells) and the important cytokine players involved (including IL-18, TNF, IL-1b, IFN-gamma, IL-6 and IL-17)
Olink panels targeting inflammation-related proteins suggest new pathophysiological mechanisms across diverse disease areas. This brief review shows how cytokines, chemokines and other immune- and inflammatory proteins are integrally involved with infectious disease (COVID-19 response), neurology (traumatic brain injury), digestive disorders (ulcerative colitis) and skin disease (atopic dermatitis).e and leading to major changes across tissues and organs.
Dr. Krolewski and his team at the Harvard Medical School found 56 proteins to be significant in diabetic kidney disease patients. Potentially, these could serve as prognostic biomarkers for disease progression and treatment response. This is how adding proteomics to the methodologies elevated their research.
Want to learn more?
Here you will find the latest list of publications that have used Olink’s panels for protein biomarker discovery in the reported studies, or which have reviewed our technology. The publications are grouped according to year of publications.
With our in-house experts, digital tools and technical document library, we support you throughout the whole process of running your project, from study design to data interpretation.
Throughout pharmaceutical development and academic/clinical research, Olink provides actionable insights through protein biomarkers across an extensive range of application areas, covering all aspects of human biology in health and disease.
Protein data points generated
Publications listed on website